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Introduction: Knowledge of longitudinal progression in mild Alzheimer’s disease (AD) is required for the evaluation
of disease-modifying therapies. Our aim was to observe the effects of long-term cholinesterase inhibitor (ChEI)
therapy in mild AD patients in a routine clinical setting.
Methods: This was a prospective, open-label, non-randomized, multicenter study of ChEI treatment (donepezil,
rivastigmine or galantamine) conducted during clinical practice. The 734 mild AD patients (Mini-Mental State
Examination (MMSE) score 20 to 26) were assessed at baseline and then semi-annually over three years. Outcome
measures included the MMSE, Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Clinician’s
Interview-Based Impression of Change (CIBIC) and Instrumental Activities of Daily Living (IADL) scale.
Results: After three years of ChEI therapy, 31% (MMSE) and 33% (ADAS-cog) of the patients showed improved/
unchanged cognitive ability, 33% showed improved/unchanged global performance and 14% showed improved/
unchanged IADL capacity. Higher mean dose of ChEI and lower educational level were both predictors of more
positive longitudinal cognitive and functional outcomes. Older participants and those with a better IADL score at
baseline exhibited a slower rate of cognitive decline, whereas younger participants and those with higher cognitive
status showed more preserved IADL ability over time. Gender and apolipoprotein E (APOE) genotype showed
inconsistent results. Prediction models using the abovementioned scales are presented.
Conclusions: In naturalistic mild AD patients, a marked deterioration in IADL compared with cognitive and global
long-term outcomes was observed, indicating the importance of functional assessments during the early stages of
the disease. The participants’ time on ChEI treatment before inclusion in studies of new therapies might affect their
rate of decline and thus the comparisons of changes in scores between various studies. An increased
understanding of expected disease progression in different domains and potential predictors of disease progression
is essential for assessment of future therapies in AD.Introduction
Alzheimer’s disease (AD) is an insidiously progressive neu-
rodegenerative disorder characterized by multiple cogni-
tive deficiencies, including increasing impairment in
memory, orientation, language and executive ability, as
well as deterioration of functional capacity [1]. Currently,
the main treatment for mild-to-moderate AD is acetyl-
cholinesterase inhibitors (ChEI), which have shown posi-
tive symptomatic effects on cognition and function
compared with a placebo in randomized clinical trials [2].* Correspondence: carina.wattmo@skane.se
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2013Novel ‘disease-modifying’ therapies attempt to block
the course of AD in the early phase [3]. Because
placebo-controlled clinical trials of more than six months
duration in untreated individuals with AD are considered
unethical, new longer studies are instead being conducted
on patients who are already being treated with ChEI.
Treatment strategies include various drug candidates
that mainly aim to interfere with biological changes
occurring in the brain during AD, such as the forma-
tion of beta-amyloid (Aβ) plaques. Hence, several re-
search efforts, including active immunization with Aβl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-Aβ antibodies, are targeted towards preventing Aβ
deposition. One study, in which AD patients were ac-
tively immunized with Aβ42, reported clearance of amyl-
oid plaques but no improvement in time to severe
dementia or survival [4]. One explanation may be that
immunotherapy is effective only in the mild stages of
AD. Using pooled data from the two phase 3 passive
immunization trials of solanezumab, the analyses dem-
onstrated a significant slowing of cognitive decline and a
trend towards slower deterioration in instrumental activ-
ities of daily living (IADL) after 80 weeks among individ-
uals with mild but not moderate AD [5]. Furthermore, a
six-month randomized trial of mild AD patients showed
that souvenaid, a medical food product containing pre-
cursors and other specific nutrients required to enhance
synapse formation, significantly increased memory per-
formance in comparison with a placebo [6].
The majority of previous long-term extensions of clin-
ical trials [7-9] and naturalistic studies of ChEI treat-
ment in AD [10,11] have enrolled participants in both
mild and moderate stages; hence, for this combined co-
hort, the cognitive, global and functional disease pro-
gression are well described. Few longitudinal studies
have reported on progression in different domains exclu-
sively in mild AD patients. This knowledge is essential
to compare the trajectories of those who have received a
new therapy in addition to ChEI with those of patients
treated only with ChEI, especially since therapies that
may modify disease progression in AD require thorough
long-term evaluation.
In some clinical trials of immunotherapy, the treatment
arms were stratified into presence/absence of the genetic
risk factor apolipoprotein E (APOE) ε4 allele. Exploratory
data analyses from the humanized monoclonal anti-Aβ
antibody bapineuzumab trial observed that non-carriers of
the APOE ε4 allele responded better cognitively than car-
riers [12]. Studies have shown contradicting results re-
garding the impact of the ε4 allele on cognitive response
to ChEI treatment [13,14]. Possible predictors of disease
progression and empirical models of the expected rate of
change in cognition and IADL have not been analyzed ex-
clusively in mild AD patients.
The aims of this study were to describe cognitive, glo-
bal and functional longitudinal progression in mild AD, to
identify the socio-demographic and clinical factors, such
as APOE genotype that influence these outcomes, and




The Swedish Alzheimer Treatment Study (SATS) was
undertaken to assess the longitudinal effectiveness of ChEItreatment (donepezil, rivastigmine or galantamine) over
three years in AD patients in clinical practice. SATS is a
prospective, open-label, observational, non-randomized,
multicenter study that was reported at length in an
earlier publication [10]. In total, 1,258 patients with
predominantly mild-to-moderate AD were enrolled
from 14 participating memory clinics across Sweden up
until April 2008. Of these, all 734 individuals in the
mild stage, that is, those participants with baseline
Mini-Mental State Examination (MMSE) [15] scores
ranging from 20 to 26, were included in the present
analyses.
Outpatients aged 40 years and over who received a clin-
ical diagnosis of dementia as defined by the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-
IV) [16] and had possible or probable AD according to the
criteria of the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) [17] were considered for inclusion in SATS. Fur-
ther inclusion criteria were that the participants had a
knowledgeable caregiver, were living at home at the time of
diagnosis and were assessable with MMSE at the start of
ChEI treatment (baseline). Patients who did not fulfill the
diagnostic criteria for AD, those already receiving active
ChEI treatment or individuals with contraindications to
ChEI were excluded from the study. Concomitant medica-
tions other than ChEIs were documented at baseline and
permitted during the study, with the exception of
memantine.
All patients and/or caregivers gave their written in-
formed consent to participate in SATS, which was
conducted according to the provisions of the Helsinki
Declaration and was approved by the Ethics Committee
of Lund University, Lund, Sweden.
The patients were evaluated in a well-structured
follow-up program, which assessed cognition, global per-
formance and functional capacity at the start of ChEI
treatment, after two months (MMSE and global rating
only), and semi-annually for a period of three years.
After recruitment in SATS and evaluation at baseline,
patients were prescribed ChEI according to the approved
product recommendations. The choice of treatment
(donepezil, rivastigmine or galantamine) was left entirely
to the physician’s discretion and professional judgment.
The ChEI dose was recorded after two months of treat-
ment, and every six months after baseline assessment.
Trained dementia nurses assessed the functional cap-
acity of participants through caregiver interviews.
Outcome measures
Cognitive ability was assessed using the MMSE scale, with
a range from 0 to 30, in which a lower score indicates
more impaired cognition, and using the Alzheimer’s
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(0 to 70 points) [18], in which a lower score indicates bet-
ter cognition. The Clinician Interview-Based Impression
of Change (CIBIC) [19] was used as a global measure of
‘change from baseline’.
Ability to perform daily activities was assessed using
the IADL scale [20] that consists of the following eight
items: ability to i) use the telephone, ii) go shopping, iii)
prepare food, iv) undertake housekeeping activities, v)
do laundry, vi) travel independently, vii) be responsible
for own medications and viii) handle finances. Each item
was scored from 1 (no impairment) to 3 to 5 (severe im-
pairment), allowing a total range of 8 to 31 points. Some
of the instrumental tasks might be gender-dependent
among the older generation. Therefore, a mathematical
correction of the sum of the IADL scores was performed,
to prevent those tasks from affecting the results. The for-
mula used the data from the rated items to estimate a total
score within the range of the total IADL scale [21].
For each assessment, mean MMSE, ADAS-cog and
IADL changes from baseline with 95% confidence inter-
vals (CI) were calculated. To facilitate comparisons
among these scales, changes in the scores calculated as
positive values should be interpreted as indicating im-
provement and those calculated as negative values
interpreted as indicating decline. Percentages of im-
proved/unchanged patients, pre-defined as those who
showed an improvement or no change (≥0 points differ-
ence) at the respective assessment, were also calculated
for the MMSE, ADAS-cog and IADL scales. The assess-
ments of change in global performance from the start of







































Baseline (n = 716) After 1 year (n = 561)
Figure 1 IADL, dependence in IADL items. Percentage of mild AD patie
(IADL score 2 to 5) at baseline and after one, two and three years of ChEI t
Instrumental Activities of Daily Living.point scale that varies from 1 (very much improved) to 7
(marked worsening), with 4 indicating no change. No
guidelines or descriptors were provided to define the in-
dividual ratings. The classification between, for example,
minimally improved or very much improved was left to the
physician’s clinical judgment. In Figure 1, the patients who
could not perform an individual IADL task independently
(IADL score 2 to 5) were categorized as ‘need assistance’.
Statistical analyses
The IBM Statistical Package for the Social Sciences
(SPSS) software (version 21.0; IBM Corporation, Armonk,
NY, USA) was used to perform statistical analyses. The
level of significance was defined as P <0.05 if not other-
wise specified. Observed-case analyses were performed to
avoid overestimation of the treatment effect by imputing
higher, earlier outcome scores in a longitudinal study of a
progressively deteriorating disease. Parametric tests were
used because of the large sample and the approximately
normally distributed continuous potential predictors. A t-
test was used to compare the differences between the
means obtained for two independent groups, and a χ2 test
was computed to analyze categorical variables. Pearson’s
correlation coefficient was calculated to investigate any
linear associations between continuous variables.
Mixed, linear and non-linear fixed and random coeffi-
cient regression models [22] using the individual as a
hierarchical variable (that is, to allow intra-individual
correlation) were performed. In addition, the mixed-
effects models take into consideration the varying number
of assessment information available for each patient and



















After 2 years (n = 416) After 3 years (n = 286)
nts who are not able to perform individual IADL tasks independently
reatment. AD, Alzheimer’s disease; ChEI, cholinesterase inhibitor; IADL,
Table 1 Socio-demographic and clinical characteristics
(n = 734)
Variable
Female gender 473 (64%)
APOE ε4 carrier, (n = 718) 493 (69%)
Solitary living at baseline 267 (36%)
Anti-hypertensives/Cardiac therapy 290 (40%)
Anti-diabetics 38 (5%)
Lipid-lowering agents 94 (13%)
Estrogens 52 (7%)




Variable Mean ± standard
deviation
Estimated age at onset (years) 72.3 ± 7.1
Estimated duration of AD at baseline (years) 2.9 ± 2.0
Age at first assessment (years) 75.2 ± 6.8
Education (years) 9.6 ± 2.6
MMSE score at baseline 23.4 ± 2.0
ADAS-cog score (0–70) at baseline 17.5 ± 6.7
IADL score at baseline 14.7 ± 5.0
Number of concomitant medications at
baseline
2.9 ± 2.4
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE,
apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; MMSE,
Mini-Mental State Examination; NSAIDs, non-steroidal anti-inflammatory drugs.
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individuals who dropped out during the study contributed
information during the time of participation; thus, we con-
sidered the trajectories of all patients.
Time was defined as the exact number of months be-
tween the start of ChEI treatment and each assessment,
which indicated that all data points were used at the ac-
tual time intervals. To adjust for baseline differences, the
initial cognitive or functional scores for each individual
and their interaction with linear and quadratic terms for
months in the study (to enable a non-linear rate of
change in the models) were included as fixed effects,
that is, time in months (or time in months2) × MMSE
(ADAS-cog or IADL) baseline score. Hence, the de-
pendent variables were the cognitive or functional scores
assigned at the second and subsequent evaluations for
each patient; thus, the mixed-effects models do not
intend to predict the scores at the start of ChEI treat-
ment. The random terms in the models were an inter-
cept and time in months, with a variance components
covariance matrix. Several socio-demographic and clin-
ical characteristics were included as fixed effects. The
potential predictors analyzed were classical risk factors,
such as age at the start of ChEI therapy (in years), the
clinician’s estimate of age at onset (in years), gender,
years of education, whether a carrier of the APOE ε4
allele (no/yes), whether living alone (no/yes), number
of medications at baseline and whether taking specific
concomitant medications (no/yes for each group) in-
cluding antihypertensive/cardiac therapy, anti-diabetics,
lipid-lowering agents, estrogens, non-steroidal anti-
inflammatory drugs (NSAIDs)/acetylsalicylic acid, anti-
depressants, antipsychotics and anxiolytics/sedatives/
hypnotics. The effect of ChEI treatment was analyzed
using different drug agents and dosages. Lastly, some
biologically plausible interactions with disease severity
at the start of treatment or with time in the study were
included in the mixed-effects models; these were gen-
der, education, age and APOE genotype.
The ChEI drugs were coded as a set of dummy vari-
ables. The dose could vary during the treatment period
for an individual patient and between patients. For that
reason, the mean dose used during the entire follow-up
period was calculated for each patient. To obtain a simi-
lar metric for percentage maximum dosage for each of
the three ChEI drugs, the mean dose was divided by the
maximum recommended dose for each agent, that is, 10
mg for donepezil, 12 mg for rivastigmine (oral therapy)
and 24 mg for galantamine. The term ‘type of ChEI ×
dose’ was also included in the models. Non-significant
variables (P >0.05) were removed in a backward stepwise
elimination manner. The hierarchical principle was ap-
plied in these analyses; terms that appeared in interac-
tions were not considered for elimination.Results
Baseline characteristics
The socio-demographic and clinical characteristics of
the 734 mild AD patients are shown in Table 1. Male pa-
tients had significantly more years of education (mean ±
standard deviation (SD), 10.2 ± 3.0 vs 9.3 ± 2.4 years; t
(730) = 4.12; P <0.001) and a lower IADL capacity at the
start of ChEI treatment (15.4 ± 5.1 vs 14.3 ± 5.0 points; t
(714) = 2.94; P = 0.003) compared with females. No sig-
nificant differences in age, cognitive ability or number of
concomitant medications at baseline were found be-
tween genders.
Individuals carrying the APOE ε4 allele (69%) were
younger on average (74.4 ± 6.9 vs 76.6 ± 6.5 years;
t(716) = 4.09; P <0.001), had an earlier onset of AD
(71.4 ± 7.2 vs 73.9 ± 6.7 years; t(713) = 4.50; P <0.001)
and had a higher IADL capacity at baseline (14.3 ± 5.1
vs 15.3 ± 4.9 points; t(698) = 2.57; P = 0.010) compared
with non-carriers. No differences in years of education,
cognitive ability or number of concomitant medications
at the start of ChEI treatment were detected between
carriers and non-carriers of the APOE ε4 allele.
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lower IADL capacity (n = 716, r = 0.326, P <0.001) and
greater number of concomitant medications at baseline
(n = 734, r = 0.228, P <0.001). In addition, lower IADL
capacity and more concomitant medications correlated
weakly (n = 716, r = 0.194, P <0.001) with each other.
Weak linear relationships between older age and lower
level of education (n = 732, r = −0.130, P <0.001) or
more impaired cognition (MMSE: n = 734, r = −0.097,
P = 0.008; ADAS-cog: n = 724, r = 0.181, P <0.001) at
the start of ChEI therapy were found.
Longitudinal outcomes in mild AD
The mean MMSE, ADAS-cog and IADL actual scores
and the changes from baseline scores during three years
are shown in Table 2. The percentages of patients who
showed improvement or remained unchanged at each
visit according to these measures are also reported. In
Table 3, the above-mentioned results are presented sep-
arately for APOE ε4-carriers and non-carriers. The
changes in global performance (CIBIC) from the start of
ChEI treatment over the three-year study are illustrated
in Figure 2. After one year, 23% of the remaining SATS
participants with mild AD were globally improved and
38% unchanged, after two years, the proportions were
13% and 29%, respectively, and after three years, the pro-
portions were 12% and 21%. The percentage of patients
who needed help to perform individual IADL items is
displayed in Figure 1. At baseline, 45% to 65% could not
perform usual IADL tasks independently, and after three
years 70% to 85% of the remaining mild AD patients in
the study needed assistance with IADLs.
ChEI therapy
Of the 734 patients, 354 (48%) received donepezil, 162
(22%) rivastigmine and 218 (30%) galantamine. After
one year, the mean ± SD doses of donepezil, rivastigmine
and galantamine were 7.7 ± 2.6, 7.6 ± 2.9 and 18.4 ± 4.4
mg, respectively. After two years, they were 8.1 ± 2.5,
8.1 ± 2.9 and 19.4 ± 4.5 mg, and after three years the
doses were 8.4 ± 2.4, 8.3 ± 2.7 and 20.3 ± 4.2 mg,
respectively.
Dropout analyses
Overall, 58% of the mild AD patients did not complete the
three-year study. The reasons for dropout from the study
were admission to nursing home (12%, n = 87), side effects
(8%, n = 57), initiation of concomitant memantine therapy
(6%, n = 42), compliance problems (5%, n = 38), death
(5%, n = 35), withdrawal of informed consent (5%, n = 35),
switching to another study (4%, n = 31), poor effect/deteri-
oration (4%, n = 28), somatic disease assumed unrelated
to AD (3%, n = 19), switching to another ChEI agent (2%,
n = 15), and other reasons (5%, n = 37).The patients who remained in SATS for the complete
three-year follow-up period exhibited significantly bet-
ter cognitive (mean ± SD; MMSE, 23.6 ± 2.0 vs 23.1 ±
1.9 points; t(732) = 3.62; P <0.001; ADAS-cog, 16.1 ±
6.8 vs 18.4 ± 6.5 points; t(722) = −4.74; P <0.001) and IADL
(13.5 ± 4.6 vs 15.5 ± 5.2 points; t(714) = −5.48; P <0.001)
abilities at baseline than patients who dropped out, and re-
ceived a greater percentage of the maximum recommended
ChEI dose during the study (69 ± 17 vs 59 ± 18%; t(732) =
7.50; P <0.001). The other patient characteristics of
gender, presence of the APOE ε4 allele, solitary living,
age at onset, age at the start of ChEI treatment, years of
education, number of concomitant medications and
specific medications received did not differ between the
completers and those who discontinued the study.Predictors of longitudinal cognitive and functional
outcomes
In the mixed-effects models, only patients with three or
more assessments (n = 656, 89.4%) were included, in
order to enable analyses of a non-linear rate of cognitive
or functional change. The models were performed (3,280
data points) to identify the socio-demographic and clin-
ical factors that affected the long-term trajectories of
mild AD patients. The percentages of variance that
accounted for the dependent variable, regarding all fixed
predictors, were 28.6% for MMSE, 37.6% for ADAS-cog,
and 60.9% for IADL, indicating a moderate to very good
fit of the models (P <0.001). The mixed-effects models,
significant predictors, and unstandardized β coefficients
with 95% CI are presented in Table 4. Male individuals
(MMSE only), non-carriers of the APOE ε4 allele
(ADAS-cog only), those with more preserved IADL abil-
ity at baseline and patients receiving a higher mean dose
of ChEI during the study (irrespective of drug agent)
exhibited a more favorable longitudinal cognitive out-
come. Individuals living with a family member, those
with better cognitive status at baseline and patients re-
ceiving a higher ChEI dose showed less deterioration in
IADL during the three-year study.
The interaction effects of cognitive severity, age at
baseline, time in months from the start of ChEI therapy,
and years of education showed that these variables can-
not be interpreted separately. Older individuals with
mild AD exhibited a better long-term cognitive outcome
compared with younger individuals. For example, 85-
year-old patients with a baseline MMSE score of 23
demonstrated, on average, 2.3 points better than 65-
year-old patients. Similarly, 85-year-old patients with a
baseline ADAS-cog score of 18 showed an additional
6.4 points better compared with 65-year-old patients
after three years of ChEI treatment. In contrast, the
corresponding mean outcome in IADL score was 0.8
Table 2 Changes in cognitive and functional abilities during three years of ChEI treatment in mild AD
Variable 2 months 6 months 12 months 18 months 24 months 30 months 36 months
(n = 706) (n = 662) (n = 597) (n = 521) (n = 450) (n = 374) (n = 306)
Completion rate (%) 96.2 90.2 81.3 71.0 61.3 51.0 41.7
MMSE scorea 24.0 (23.8, 24.2) 23.5 (23.3, 23.8) 22.8 (22.5, 23.2) 22.1 (21.7, 22.5) 21.4 (20.9, 21.8) 21.1 (20.5, 21.6) 20.6 (20.0, 21.2)
ADAS-cog (0 to 70) scorea 17.4 (16.8, 18.0) 18.3 (17.6, 19.0) 19.5 (18.6, 20.3) 20.1 (19.1, 21.1) 21.3 (20.0, 22.7) 21.7 (20.2, 23.2)
IADL scorea 15.8 (15.4, 16.2) 17.0 (16.6, 17.5) 17.9 (17.4, 18.5) 18.8 (18.2, 19.4) 19.4 (18.7, 20.1) 19.8 (19.1, 20.6)
MMSE score, change from baselinea 0.61 (0.43, 0.78) 0.19 (−0.04, 0.42) −0.57 (−0.86, −0.28) −1.31 (−1.66, −0.96) −2.20 (−2.64, −1.77) −2.54 (−3.06, −2.02) −3.10 (−3.66, −2.54)
ADAS-cog (0 to 70) score, change from baselinea −0.15 (−0.65, 0.34) −1.20 (−1.77, −0.63) −2.58 (−3.27, −1.90) −3.81 (−4.59, −3.03) −4.97 (−6.09, −3.85) −6.12 (−7.35, −4.89)
IADL score, change from baselinea −1.12 (−1.34, −0.91) −2.48 (−2.78, −2.17) −3.64 (−4.01, −3.26) −4.75 (−5.18, −4.33) −5.54 (−6.06, −5.02) −6.27 (−6.86, −5.68)
MMSE score, improved/unchanged patients (%) 72.7 64.1 55.0 46.9 41.9 38.2 33.0
ADAS-cog (0 to 70) score, improved/unchanged
patients (%)
55.3 48.8 41.8 36.7 32.9 31.1
IADL score, improved/unchanged patients (%) 49.7 34.2 24.3 18.0 14.8 13.8
aMean (95% confidence interval).
For clarity, clinical improvements for all scales have been tabulated as positive changes from the start of ChEI treatment (baseline).


















Table 3 Changes in scores during three years of ChEI treatment in mild AD by APOE genotype
MMSE scorea MMSE score, change from baselinea MMSE score, improved/unchanged patients (%)
Number of non-carriers/ε4-carriersb Non-carriers ε4-carriers P- value Non-carriers ε4-carriers P-value Non-carriers ε4-carriers P-value
Baseline (n = 225/493) 23.3 (23.0, 23.5) 23.4 (23.2, 23.6) 0.326
2 months (n = 213/469) 24.0 (23.6, 24.4) 24.0 (23.8, 24.3) 0.843 0.64 (0.28, 1.00) 0.60 (0.39, 0.80) 0.834 73.2 72.7 0.926
6 months (n = 194/423) 23.5 (23.0, 23.9) 23.5 (23.2, 23.9) 0.864 0.20 (−0.20, 0.59) 0.17 (−0.12, 0.46) 0.920 61.9 65.2 0.417
12 months (n = 178/388) 22.7 (22.1, 23.3) 22.9 (22.5, 23.3) 0.597 −0.53 (−1.10, 0.04) −0.56 (−0.89, −0.22) 0.945 56.2 54.4 0.716
18 months (n = 145/320) 21.7 (20.9, 22.5) 22.3 (21.9, 22.8) 0.189 −1.53 (−2.29, −0.78) −1.18 (−1.57, −0.80) 0.420 49.0 46.3 0.617
24 months (n = 130/292) 21.0 (20.0, 22.0) 21.5 (21.0, 22.1) 0.361 −2.52 (−3.45, −1.60) −2.05 (−2.54, −1.57) 0.377 44.6 40.8 0.522
30 months (n = 97/219) 21.5 (20.5, 22.5) 20.9 (20.2, 21.6) 0.342 −2.04 (−3.03, −1.05) −2.74 (−3.36, −2.11) 0.230 47.4 34.7 0.034
36 months (n = 91/199) 21.0 (19.9, 22.2) 20.3 (19.6, 21.1) 0.325 −2.81 (−3.83, −1.80) −3.26 (−3.95, −2.57) 0.471 35.2 31.7 0.591
ADAS-cog (0 to 70) scorea ADAS-cog (0 to 70) score, change from
baselinea
ADAS-cog (0 to 70) score, improved/unchanged
patients (%)
Number of non-carriers/ε4-carriersb Non-carriers ε4-carriers P-value Non-carriers ε4-carriers P-value Non-carriers ε4-carriers P-value
Baseline (n = 220/488) 17.8 (17.0, 18.6) 17.1 (16.6, 17.7) 0.220
6 months (n = 187/414) 16.8 (15.9, 17.8) 17.6 (16.8, 18.3) 0.277 0.84 (0.09, 1.58) −0.57 (−1.22, 0.08) 0.011 63.0 51.5 0.010
12 months (n = 171/376) 18.1 (16.8, 19.4) 18.5 (17.6, 19.3) 0.666 0.06 (−0.84, 0.96) −1.78 (−2.50, −1.05) 0.004 57.7 44.5 0.005
18 months (n = 137/306) 19.4 (17.7, 21.1) 19.5 (18.5, 20.5) 0.893 −1.88 (−3.30, −0.47) −2.89 (−3.68, −2.11) 0.185 48.1 38.8 0.075
24 months (n = 117/274) 20.4 (18.2, 22.5) 20.1 (18.9, 21.3) 0.812 −3.34 (−4.98, −1.70) −4.07 (−4.96, −3.18) 0.409 43.5 33.3 0.065
30 months (n = 92/203) 20.7 (18.3, 23.1) 21.7 (20.1, 23.3) 0.526 −3.71 (−5.85, −1.58) −5.54 (−6.87, −4.22) 0.139 42.2 28.7 0.031
36 months (n = 85/180) 20.9 (18.2, 23.5) 22.2 (20.3, 24.0) 0.427 −4.96 (−7.24, −2.68) −6.78 (−8.28, −5.29) 0.181 40.5 26.8 0.032
IADL scorea IADL score, change from baselinea IADL score, improved/unchanged patients (%)
Number of non-carriers/ε4-carriersb Non-carriers ε4-carriers P-value Non-carriers ε4-carriers P-value Non-carriers ε4-carriers P-value
Baseline (n = 219/481) 15.3 (14.7, 16.0) 14.3 (13.8, 14.7) 0.010
6 months (n = 189/413) 16.3 (15.6, 17.0) 15.5 (15.0, 16.0) 0.081 −1.07 (−1.45, −0.69) −1.14 (−1.41, −0.88) 0.758 48.1 50.6 0.597
12 months (n = 175/379) 17.6 (16.8, 18.4) 16.8 (16.2, 17.4) 0.123 −2.31 (−2.80, −1.82) −2.55 (−2.93, −2.16) 0.482 34.3 34.8 0.923
18 months (n = 142/311) 18.6 (17.6, 19.6) 17.6 (16.9, 18.3) 0.099 −3.64 (−4.29, −2.99) −3.63 (−4.09, −3.16) 0.974 26.6 23.4 0.477
24 months (n = 128/283) 19.8 (18.7, 20.9) 18.4 (17.7, 19.1) 0.029 −5.13 (−5.96, −4.29) −4.60 (−5.10, −4.10) 0.268 18.4 17.9 0.889
30 months (n = 95/216) 19.9 (18.7, 21.1) 19.1 (18.3, 19.9) 0.273 −5.11 (−6.07, −4.15) −5.71 (−6.34, −5.09) 0.301 16.3 14.4 0.728
36 months (n = 91/191) 20.3 (18.9, 21.7) 19.7 (18.8, 20.6) 0.500 −6.23 (−7.31, −5.14) −6.31 (−7.03, −5.60) 0.895 17.0 12.1 0.266
aMean (95% confidence interval).
bNo difference in dropout was found between APOE ε4-carriers and non-carriers, χ2(1) = 0.148, P = 0.700.
For clarity, clinical improvements for all scales have been tabulated as positive changes from the start of ChEI treatment (baseline).




























































Figure 2 CIBIC, changes in global performance. The changes in global performance (CIBIC) from the start of ChEI treatment over three years
in mild AD. CIBIC score 1 to 3 was considered as improvement, 4 as unchanged and 5 to 7 as deterioration. Among the remaining patients
in the study, 61% exhibited global improvement or no changes after one year, 43% after two years and 33% after three years of ChEI therapy.
AD, Alzheimer’s disease; ChEI, cholinesterase inhibitor; CIBIC, Clinician’s Interview-Based Impression of Change.
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individual.
Furthermore, there was an interaction effect between
years of education and time in the study. A higher level
of education implied increased cognitive and functional
impairments over time. For example, a patient with 15
years of education exhibited an additional 1.6 points of
MMSE, 2.7 points of ADAS-cog and 2.2 points of IADL
mean deterioration after 3 years compared with an indi-
vidual with 9 years of education.
If not otherwise specified, the arbitrary examples
presented in these calculations were based on an average
patient that was aged 75 years, was a carrier of the
APOE ε4 allele, living with a family member, had 10
years of education, exhibited an MMSE score of 23,
ADAS-cog score of 18, IADL score of 15, and received
65% of the maximum recommended dose of ChEI.
The background variables age at onset, number of
medications and specific concomitant medications, type
of ChEI agent, type of ChEI × dose and the interaction
effects of gender or APOE genotype with disease severity
or time in the study were not significant when included
in the mixed-effects models.
Prediction models
Non-linear regression models for calculation of the pre-
dicted MMSE, ADAS-cog or IADL score for a cohort of
ChEI-treated mild AD patients, based on the respective
baseline score are provided. These equations intend to
predict the scores at subsequent assessments over a
three-year period. The models explained a substantial
degree of variance in the data set, that is, demonstrated
a good fit, MMSE: (R2 = 0.261, R = 0.511, P <0.001),
ADAS-cog: (R2 = 0.385, R = 0.621, P <0.001), and IADL:
(R2 = 0.592, R = 0.769, P <0.001).Predicted MMSE score:
Y^ ¼ 7:6014 0:4374 tð Þ þ 0:7116 xið Þ
þ 0:0138 txið Þ
Predicted ADAS-cog score:
Y^ ¼ 2:7835 0:0537 tð Þ
þ 0:8867 xið Þ− 0:0073 xi2
 þ 0:0161 txið Þ
Predicted IADL score:
Y^ ¼ −6:1756þ 0:3140 tð Þ




− 0:0032 txið Þ
Where t = time in months between the baseline score
and the actual visit, xi = baseline MMSE (ADAS-cog or
IADL) score.
The MMSE and ADAS-cog prediction models are
illustrated in Figure 3a, b, respectively. The SATS pa-
tients’ actual mean scores with 95% CI are also
presented in the figures, together with expected decline
in untreated individuals. Regarding MMSE, a reported
deterioration of 1.4 to 1.8 points per year in mild AD
was used [23], and the predicted ADAS-cog decline was
calculated based on two previously reported baseline-
dependent empirical models of untreated AD [24,25].
Discussion
In this three-year study of ChEI treatment in mild AD in a
routine clinical setting, we found that patients’ cognitive
ability and global performance were more preserved than
their functional capacity. Using mixed-effects models,
we found that a higher mean dose of ChEI (regardless
of drug agent) and a lower level of education were pre-
dictors of more preserved longitudinal cognitive and
Table 4 Factors affecting the long-term outcome with MMSE, ADAS-cog or IADL score as dependent variables
MMSE ADAS-cog IADL
Percentage of variance accounted for, all fixed terms 28.6%, P <0.001 37.6%, P <0.001 60.9%, P <0.001
Significant predictors in final mixed modelsa β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value
Fixed terms
Intercept −25.751 0.022 −14.101 0.048 0.808 0.728
(−47.709, −3.793) (−28.099, −0.102) (−3.747, 5.363)
Time in months from baseline −0.924 <0.001 0.480 0.019 0.154 <0.001
(−1.201, −0.648) (0.078, 0.881) (0.069, 0.239)
Baseline assessment score 2.198 <0.001 1.696 <0.001 1.530 <0.001
(1.272, 3.124) (0.931, 2.462) (1.262, 1.798)
Baseline assessment score2 ns ns −0.021 <0.001
(−0.029, −0.013)
Time in months × Baseline assessment score 0.028 <0.001 0.014 <0.001 −0.001 0.512
(0.019, 0.036) (0.008, 0.021) (−0.005, 0.003)
Time in months2 × Baseline assessment score −0.00007 <0.001 0.0002 0.002 −0.00006 0.043
(−0.0001, −0.00004) (0.00006, 0.0003) (−0.0001, −0.000002)
Background variables:
Gender (male = 0, female = 1) −0.582 0.001 ns ns
(−0.233, −0.931)
APOE ε4 carrier (no = 0, yes = 1) ns 1.278 0.015 ns
(2.307, 0.249)
Solitary living (no = 0, yes = 1) ns ns 0.776 0.001
(1.253, 0.299)
Education (years) 0.089 0.011 −0.111 0.281 −0.051 0.328
(0.021, 0.158) (−0.312, 0.090) (−0.152, 0.051)
Time in months × Education, years −0.010 0.002 0.016 0.017 0.011 0.001
(−0.016, −0.004) (0.003, 0.028) (0.005, 0.018)
Age at first assessment (years) 0.491 0.001 0.285 0.002 0.042 0.023
(0.202, 0.780) (0.101, 0.469) (0.006, 0.078)
Time in months × Age 0.004 0.003 −0.009 <0.001 ns
(0.001, 0.006) (−0.014, −0.004)
Baseline assessment score × Age −0.022 <0.001 −0.015 0.004 ns



















Significant predictors in final mixed modelsa












(−0.135, −0.062) (0.117, 0.332)
MMSE score at baseline na na −0.238 <0.001
(−0.358, −0.118)
ChEI doseb 0.010 0.049 −0.044 0.002 −0.013 0.048
(0.00004, 0.019) (−0.071, −0.017) (−0.026, −0.0001)
Random terms (variance)
Intercept 2.097 <0.001 17.298 <0.001 5.539 <0.001
(1.647, 2.669) (13.849, 21.606) (4.473, 6.858)
Time in months 0.026 <0.001 0.086 <0.001 0.027 <0.001
(0.022, 0.031) (0.071, 0.104) (0.022, 0.032)
Age at onset, number of medications and specific concomitant medications used at baseline and the variable comparing the ChEI agents were not significant.
β values were unstandardized and are expressed per one unit increase for continuous variables and for the condition present in dichotomous variables.
aBaseline assessment score = MMSE, ADAS-cog or IADL, respectively.
bMean percentage of the maximum recommended dose, that is, 10 mg for donepezil, 12 mg for rivastigmine and 24 mg for galantamine.
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE, apolipoprotein E; ChEI, cholinesterase inhibitors; CI, confidence interval; IADL, Instrumental Activities of Daily Living; MMSE,
Mini-Mental State Examination; na not applicable; ns not significant.












































Mean actual scores (ChEI-treated) Predicted model (ChEI-treated)
Months






























Mean actual scores (ChEI-treated) Predicted model (ChEI-treated)
Predicted model Ito (untreated) Predicted model Stern (untreated)
Months
724 611 553 449 395 298 269 n
b
Figure 3 Prediction of cognitive outcome during three years of ChEI treatment. a) Predicted MMSE mean scores calculated from our non-
linear regression model of ChEI-treated mild AD patients. The participants’ actual mean scores with 95% CI are also presented in the figure. The
shaded area shows the decline of 1.4 to 1.8 MMSE points/year based on historical untreated individuals with mild AD [23]. b) Predicted ADAS-
cog mean scores calculated from our non-linear regression model of ChEI-treated mild AD patients. Their actual mean scores with 95% CI are
also presented in the figure. The mean predicted scores with 95% CI from two baseline-dependent prediction models of untreated AD patients
are also included in the figure for comparison [24,25]. AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive
subscale; ChEI, cholinesterase inhibitor; MMSE, Mini-Mental State Examination.
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impaired IADL at baseline exhibited a slower progres-
sion rate in cognition, while younger age, living with a
family member and higher cognitive status at baseline
were predictors of less functional deterioration during
the study. Inconsistent results regarding cognitive out-
come were found between genders and APOE genotype.
Regression models of expected decline in mild AD are
presented.
There has been increased interest in disease progression
in mild AD after new therapies such as solanezumab andsouvenaid have shown positive results in this group exclu-
sively. In the present study of mild AD, which includes all
three ChEI agents, the three-year decline in ADAS-cog
was 6.12 points and MMSE 3.10 points, suggesting a simi-
lar rate of change as in our previously described mild-to-
moderate SATS group [10,26]. The US Food and Drug
Administration has defined an improvement of at least
four points in the ADAS-cog score as clinically significant
(reported in [27,28]), and a MMSE change of three points
has been suggested to indicate a clinically significant alter-
ation in cognitive ability [29,30]. From the Alzheimer’s
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reported that the ChEI-treated participants with mild AD
deteriorated, on average, 9.25 points in ADAS-cog and
4.19 points in MMSE scores after two years in the study.
The corresponding two-year mean decline in our cohort
was considerably less, 3.81 and 2.20 points, respectively.
An 18-month randomized controlled trial of tarenflurbil
in mild AD showed 6.44 points ADAS-cog and 3.27 points
MMSE mean deterioration in the placebo group (most pa-
tients were treated with ChEIs and/or memantine) [32].
As a comparison, our study showed, on average, lower de-
terioration after 18 months, 2.58 and 1.31 points, respect-
ively. However, participants were included in these studies
1 year (median) and 20.5 months (mean) after AD diagno-
sis. Thus, these patients had been treated with ChEIs and/
or memantine before the baseline, whereas the baseline in
the SATS was the start of ChEI therapy. The slower dis-
ease progression observed in the SATS cohort might re-
flect the benefits of continuous ChEI therapy started
almost immediately after AD diagnosis and the positive
treatment response in the first months after initiation
(baseline).
The current study of mild AD highlights the importance
of not only assessing cognition at follow-ups, but also
IADL capacity. A moderate linear relationship (r = 0.4
to 0.7) between cognitive and functional abilities has
been observed in both untreated [33] and ChEI-treated
[34] AD patients. Our study demonstrated that individ-
uals with higher cognitive status at the start of ChEI
therapy showed greater preserved IADL capacity over
time and that those with a better IADL score at base-
line exhibited a slower rate of cognitive decline.
Patients showing a rapid functional decline have previ-
ously been shown to exhibit significantly greater im-
pairment of cognitive ability at the time of AD
diagnosis [11,35,36]. This relationship indicates that
various aspects of the patients’ capabilities (cognitive,
global, IADL) should be analyzed using multivariate
methods, and these aspects should be interpreted sim-
ultaneously because a change in one ability might affect
a change in another.
In the present ChEI-treated cohort with MMSE score
20 to 26, the rate of deterioration in IADL was faster
than in cognitive ability and global performance. A
marked decline in IADL capacity was also reported in
the above-mentioned studies of mild AD [31,32]. Func-
tional deficits have been observed as early as in amnestic
mild cognitive impairment [37]. Three years after AD
diagnosis, 70% to 85% of the remaining individuals in
our mild SATS cohort could not carry out IADL tasks
independently. The number of concomitant medications
and usage of specific medications at baseline were not
significant predictors of progression in IADL in the
multivariate mixed-effects models in the current study,suggesting that comorbidity did not influence the func-
tional outcome. These findings emphasize the import-
ance of functional evaluations even for patients in the
mild stage of AD in clinical routine, and raise the ques-
tion of whether IADL is a better and more sensitive out-
come measure than cognition in studies of potentially
‘disease-modifying’ therapies.
The rate of disease progression varies among AD pa-
tients. In particular, knowledge of prognostic factors in
mild AD exclusively is strongly limited. This study shows
that male gender, older age, a lower level of education,
absence of the APOE ε4 allele, more preserved IADL
ability and a higher mean dose of ChEI were significant
predictors of slower cognitive decline. Younger age,
lower educational level, living with a family member,
better cognitive status and a higher ChEI dose were pre-
dictors of less functional deterioration. These findings
are consistent with previous papers from the SATS in-
cluding the entire mild-to-moderate cohort [11,38].
Using a mixed-models approach, Wilkosz et al. [39] also
observed that male sex and older age were predictors of
a slower longitudinal cognitive decline in AD. Several
other studies also reported a more rapid rate of cognitive
deterioration in younger individuals [40,41], but not all
found that age was a significant predictor of decline
[42]. It is reasonable to predict that when AD is manifest
at younger ages, more hereditary early-onset and fast
progression subtypes of the disease affect the outcome
and could lead to a worse prognosis in mild AD as well.
Our finding that a lower education level was related to a
slower rate of cognitive deterioration was in agreement
with a community-based study of mild dementia [43].
Lower education has also been reported to be associated
with slower progression in mild-to-moderate AD [41,44].
Patients with low education level were assumed to have a
reduced cognitive reserve and, therefore, would be more
vulnerable to the effects of neurodegeneration. They
would also be expected to perform worse on standardized
cognitive tests that use a single threshold to identify de-
mentia, such as the MMSE and ADAS-cog. These conse-
quences of a lower education level might lead to an earlier
manifestation of the typical symptoms of AD and detec-
tion of the disease. Furthermore, diagnosis and treatment
might occur in an earlier stage, which may improve the re-
sults of AD therapy. The participants’ high level of educa-
tion in the studies of mild AD from the United States
[31,32] might be one reason for their faster cognitive de-
cline compared with the SATS cohort. Impairment in sev-
eral cognitive domains and its relation to level of
education can already be observed several years before the
clinical diagnosis of AD [45].
In the current study, the presence of at least one
APOE ε4 allele was associated with a faster rate of cog-
nitive decline when using the ADAS-cog scale but not
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with cognitive deterioration in the literature vary. Some
studies report a positive relationship of APOE ε4 with
more rapid cognitive decline in mild [46] and mild-to-
moderate AD [47], while others report no significant
influence on the rate of cognitive and functional progres-
sion [48,49], or that individuals with two ε4 alleles have
a slower clinical course of AD [50]. Explorative analyses
based on phase 2 data from passive immunization with
the anti-Aβ antibody bapineuzumab found that non-
carriers of the APOE ε4 allele had a better cognitive re-
sponse compared with ε4-carriers after 18 months [12];
however, the phase 3 trials failed to replicate these re-
sults [51]. Yet, the treatment groups have been stratified
into presence/absence of the APOE ε4 allele in some
immunotherapy studies [52]. In our naturalistic SATS
study including ChEI-treated patients with mild-to-
moderate AD, APOE ε4-carriers exhibited both a
lower cognitive response after six months of treatment
and poorer long-term outcome after three years. On
average, these individuals were younger at the start of
ChEI treatment and had a higher level of education
than the non-ε4 carriers [38]. A recent study of func-
tional ability in amnestic mild cognitive impairment
showed that patients carrying the APOE ε4 allele had
more IADL deficits compared with non-carriers [37].
These findings highlight the importance of using an ad-
vanced multivariate statistical method, such as a mixed-
effects model, to be able to take the potential predictive
characteristics into account when analyzing disease pro-
gression [53]. The better response to drug agents
observed in patients with no APOE ε4 alleles might not
be a therapeutic effect, but possibly a slower natural
decline.
Higher doses of ChEIs were related to a more favor-
able long-term cognitive and functional outcome in this
study of mild AD. These results were also observed in
the entire mild-to-moderate SATS cohort [11,38] as well
as in a meta-analysis of randomized trials [54]. More-
over, a higher ChEI dose was associated with a delay in
the need for nursing home placement [21,55]. A recent
study from our group reported for the first time a sig-
nificant relationship between a higher dose of ChEI and
less need for home help services [56]. These effects and
consequences show the importance of optimizing the
ChEI dose for the individual patient with AD.
The advantages of the present three-year treatment
study are the prospective, well-structured, regular six-
month evaluations of a large cohort of continuously
ChEI-treated mild AD patients from Swedish memory
clinics. We enrolled more ordinary patients than the
specially selected individuals usually included in clinical tri-
als by using wide inclusion criteria, and allowing concomi-
tant illnesses and medications. Moreover, the complianceto ChEI treatment in the SATS cohort was high [57].
The completion rate of 42% obtained for these partici-
pants from clinical practice was high compared with
other AD extension or naturalistic studies [26]. The
large attrition rate in all long-term AD studies may con-
tribute to a better outcome for the patients remaining in
the study, assuming that they benefit more from ChEI
therapy. The SATS is an observational, non-randomized
study, and has the limitations of an open-label design,
and no untreated placebo group because of ethical con-
cerns, similar to other AD therapy studies longer than
six months. The choice of the ChEI agent and dose was
left entirely to the individual physician’s discretion and
professional judgment.
In the future, research efforts will focus on the devel-
opment of AD starting in the early and pre-symptomatic
stages. The timing of the start of therapy during the
course of AD appears to be an essential factor that influ-
ences disease progression and the outcome of clinical
trials. Currently, new pharmacological agents, such as
immunotherapies, are being evaluated in randomized tri-
als in addition to standard therapy (ChEI and/or
memantine). Long-term observational studies of ChEI-
treated AD patients exclusively in the milder stages are
warranted to demonstrate realistic treatment expecta-
tions. The baseline-dependent prediction models of mild
AD presented in the current study might be a useful tool
to estimate the cognitive and functional outcomes that
may be expected using ChEI monotherapy over time.
Conclusions
In conclusion, an investigation of disease progression in
different domains was described in this mild AD study.
Our naturalistic SATS cohort exhibited a slower cog-
nitive decline in comparison with those previously re-
ported in the literature; however, the patients in those
studies had been treated with ChEIs and/or memantine
prior to baseline and had different socio-demographic
characteristics. When comparing changes in scores be-
tween studies, it may be important to consider the point
of time when ChEI therapy was initiated because the
first months of positive response after initiation could
imply a more favorable mean outcome over time. This
study shows that socio-demographic and clinical fac-
tors such as age, years of education and the dose of
ChEI, previously shown to affect the trajectories in
mild-to-moderate patients, might alter the outcomes
of various mild AD studies as well. The surprisingly
fast deterioration in IADL compared with cognitive
and global performance stresses the clinical import-
ance of functional evaluations during the early stages
of dementia. APOE genotype exhibited inconsistent re-
sults, which is noteworthy since this variable is used to
select patients in AD trials. Information related to
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ease, and the influence of potential predictors, is ne-
cessary for evaluation of future treatments in mild AD.
We present mathematical prediction models that could
be used to assess the long-term outcomes of new ther-
apies added to ChEI treatment.
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